Liver cancer has been difficult to conquer the mountain of medicine, once suffering from cancer, doctors can only rely on dialysis or drug maintenance, some medical device company also through the technical research and development production biochemical analyzer, hope to help patients get rid of cancer as early as possible, recently by experts on the patients with biochemical analyzer diagnosis find new ways, the following content is detailed.
Just extraction 1 ml of the blood, for less than 2 cm of lier cancer diagnosis rate of about 90%. The reporter from 29, fudan university affiliated hospital of sun yat-sen that, China's medical staff found a so far specificity, sensitivity and operability comprehensive advantages, the most obvious of the liver cancer diagnosis new method, the study is the most authoritative international clinical cancer field of academic journal the United States "journal of clinical oncology published and dispensed editor's note, is expected to change the current liver cancer screening the traditional method, and greatly promote liver cancer early, early diagnosis and treatment and found, improve patient surial.
Liver cancer for malignant degree is high, known as the king of cancer. Our country is liver cancer high-risk countries, more than 50% of the world new hair and death in patients with liver cancer in our country. Liver cancer onset conceals, more than 60% of the liver cancer patients at the first visit have entered the period, and lose the opportunity to radical treatment, the overall 5-year survival rate is only about 7%. At present, clinical diagnosis of liver cancer markers used for a child protein, hereinafter referred to as the AFP. However, a tire protein diagnosis of liver cancer of sensitivity and specific degree is not very ideal, in pregnant women, acute or chronic hepatitis, ShengShiXian tumors and gastrointestinal tumors etc the crowd may be increased also. Also, 40% of patients with clinical liver cancer a child was not elevated protein, present the negative. Therefore, specificity and sensitivity are looking for the diagnosis of liver cancer, especially high molecular markers of liver cancer early, become the key and difficult point for clinical research.
Fudan university affiliated hospital of sun yat-sen institute of liver cancer research team and fudan university department of pathology, cooperation, after three years and research, and finally, on liver cancer patients in the plasma screen by seven small RNA (microRNA) early diagnosis of liver cancer molecular markers. For less than 2 cm of lier cancer diagnostic accuracy rate near 90%, for a child of the diagnosis of liver cancer proteins recessive accuracy rate as high as 88%.
Task group study found that some plasma biological markers in the expression of hepatocellular carcinoma patients with normal person, chronic hepatitis and liver cirrhosis patient there was significant difference between, through the high throughput chip technology and real-time quantitative fluorescence screening PCR technology to seven liver cancer related plasma small RNA. The paper first ZhouJian professor said: it is well known that second liver cirrhosis and liver cancer, and most of our patients with hepatocellular carcinoma (HCC) is the development and change of the process. Research using three different people as a comparison, including healthy people and chronic hepatitis b and hepatitis b patients with liver cirrhosis, liver cancer will be in the process of the development of the crowd of different periods are incorporated into the control group, were small RNA can control the crowd with all kinds of liver cancer to distinguish, the more suitable for clinical application.
According to the author FanJia paper communication professor introduction, this new diagnosis method in the clinical application of has obvious advantages. First of all, small RNA in plasma can tolerate the degradation of RNA enzyme, very stable; Second, detection convenient and only 1 ml blood can extract for several hours to obtain the result, traumatic small, beneficial to the continuous dynamic testing and the crowd of mass screening; In addition, detection technology requirements is simple, low cost, only 100 yuan or so, easy to application. "Especially new methods can be diagnosed less than 2 cm of early, make a large number of original hepatocellular carcinoma due to lack of effective diagnosis and treatment of liver cancer patients lose opportunity to get timely treatment. And our country liver cancer patients generally 5 year's survival rates compared to about 7%, less than 2 cm of early hepatocellular carcinoma can often by removing, radiofrequency ablation and method for the radical, the 5-year survival rate was higher than 90%."
At present, this result is applying for China, the us, Japan and the European Union and the patent. The researchers will further develop contains seven small RNA detection probes of the microchip, and liver cancer in high-risk groups large-scale screening.
Just extraction 1 ml of the blood, for less than 2 cm of lier cancer diagnosis rate of about 90%. The reporter from 29, fudan university affiliated hospital of sun yat-sen that, China's medical staff found a so far specificity, sensitivity and operability comprehensive advantages, the most obvious of the liver cancer diagnosis new method, the study is the most authoritative international clinical cancer field of academic journal the United States "journal of clinical oncology published and dispensed editor's note, is expected to change the current liver cancer screening the traditional method, and greatly promote liver cancer early, early diagnosis and treatment and found, improve patient surial.
Liver cancer for malignant degree is high, known as the king of cancer. Our country is liver cancer high-risk countries, more than 50% of the world new hair and death in patients with liver cancer in our country. Liver cancer onset conceals, more than 60% of the liver cancer patients at the first visit have entered the period, and lose the opportunity to radical treatment, the overall 5-year survival rate is only about 7%. At present, clinical diagnosis of liver cancer markers used for a child protein, hereinafter referred to as the AFP. However, a tire protein diagnosis of liver cancer of sensitivity and specific degree is not very ideal, in pregnant women, acute or chronic hepatitis, ShengShiXian tumors and gastrointestinal tumors etc the crowd may be increased also. Also, 40% of patients with clinical liver cancer a child was not elevated protein, present the negative. Therefore, specificity and sensitivity are looking for the diagnosis of liver cancer, especially high molecular markers of liver cancer early, become the key and difficult point for clinical research.
Fudan university affiliated hospital of sun yat-sen institute of liver cancer research team and fudan university department of pathology, cooperation, after three years and research, and finally, on liver cancer patients in the plasma screen by seven small RNA (microRNA) early diagnosis of liver cancer molecular markers. For less than 2 cm of lier cancer diagnostic accuracy rate near 90%, for a child of the diagnosis of liver cancer proteins recessive accuracy rate as high as 88%.
Task group study found that some plasma biological markers in the expression of hepatocellular carcinoma patients with normal person, chronic hepatitis and liver cirrhosis patient there was significant difference between, through the high throughput chip technology and real-time quantitative fluorescence screening PCR technology to seven liver cancer related plasma small RNA. The paper first ZhouJian professor said: it is well known that second liver cirrhosis and liver cancer, and most of our patients with hepatocellular carcinoma (HCC) is the development and change of the process. Research using three different people as a comparison, including healthy people and chronic hepatitis b and hepatitis b patients with liver cirrhosis, liver cancer will be in the process of the development of the crowd of different periods are incorporated into the control group, were small RNA can control the crowd with all kinds of liver cancer to distinguish, the more suitable for clinical application.
According to the author FanJia paper communication professor introduction, this new diagnosis method in the clinical application of has obvious advantages. First of all, small RNA in plasma can tolerate the degradation of RNA enzyme, very stable; Second, detection convenient and only 1 ml blood can extract for several hours to obtain the result, traumatic small, beneficial to the continuous dynamic testing and the crowd of mass screening; In addition, detection technology requirements is simple, low cost, only 100 yuan or so, easy to application. "Especially new methods can be diagnosed less than 2 cm of early, make a large number of original hepatocellular carcinoma due to lack of effective diagnosis and treatment of liver cancer patients lose opportunity to get timely treatment. And our country liver cancer patients generally 5 year's survival rates compared to about 7%, less than 2 cm of early hepatocellular carcinoma can often by removing, radiofrequency ablation and method for the radical, the 5-year survival rate was higher than 90%."
At present, this result is applying for China, the us, Japan and the European Union and the patent. The researchers will further develop contains seven small RNA detection probes of the microchip, and liver cancer in high-risk groups large-scale screening.
没有评论:
发表评论